跳转至内容
Merck
CN

D-003

Supelco

1,3-二硝基甘油 溶液

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C3H6N2O7
CAS号:
分子量:
182.09
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

100 μg/mL in acetonitrile

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

pharmaceutical (small molecule)

包装形式

single component solution

储存温度

−20°C

SMILES字符串

OC(CO[N+]([O-])=O)CO[N+]([O-])=O

InChI

1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2

InChI key

ASIGVDLTBLZXNC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

1,3-Dinitroglycerin is a major plasma metabolite of the pharmaceutical vasodilator nitroglycerin. This Certified Spiking Solution® is suitable for use in chromatography or mass spectrometry-based applications in pharmaceutical research or clinical toxicology. Nitroglycerin is used to treat heart conditions such as angina and chronic heart failure.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

FlameExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

35.6 °F - closed cup

闪点(°C)

2 °C - closed cup

法规信息

危险化学品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

B Auclair et al.
Pharmaceutical research, 15(4), 614-619 (1998-05-20)
To construct a pharmacokinetic (PK) model and to determine population PK parameters of nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN). Data were obtained in thirty healthy volunteers following a single dose of a GTN reservoir transdermal patch. Blood samples were
Magnus Petersson et al.
Clinical physiology and functional imaging, 28(4), 229-234 (2008-04-04)
Patients with chronic heart failure (CHF) often require higher doses of nitroglycerin (glyceryl trinitrate, GTN) than patients with normal cardiac function to achieve a given haemodynamic goal. Two pathways leading to biotransformation of GTN have been characterized; a high-affinity pathway
W E Haefeli et al.
Clinical pharmacology and therapeutics, 52(6), 590-596 (1992-12-01)
Independent of the route of nitroglycerin administration, substantial amounts of 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl dinitrate (1,3-GDN) metabolites accumulate in humans. Thus far their pharmacologic activity in comparison to nitroglycerin in humans is unknown. To compare the venodilatory potency of
F W Lee et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 533-550 (1993-10-01)
Intravenous infusions of nitroglycerin (GTN), 1,2-glyceryl dinitrate (1,2-GDN), and 1,3-glyceryl dinitrate (1,3-GDN) were given to four conscious dogs at 10 micrograms/min, 30 micrograms/min, 50 micrograms/min, and 70 micrograms/min of GTN and 20 micrograms/min and 100 micrograms/min of GDNs. The steady
M V Wenzl et al.
British journal of pharmacology, 156(8), 1248-1255 (2009-03-04)
Vascular tolerance to nitroglycerin (GTN) may be caused by impaired GTN bioactivation due to inactivation of mitochondrial aldehyde dehydrogenase (ALDH2). As relaxation to GTN is reduced but still sensitive to ALDH2 inhibitors in ascorbate deficiency, we compared the contribution of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门